- Home
- TRBG vs CATX Comparison
TRBG vs CATX Comparison
Compare TRBG & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRBG | CATX |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | Israel | United States |
| Employees | 20 | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.6M | 97.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TRBG | CATX |
|---|---|---|
| Price | $3.77 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $9.93 |
| AVG Volume (30 Days) | 42.0K | ★ 4.1M |
| Earning Date | 09-24-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.98 | $0.78 |
| 52 Week High | $5.84 | $6.16 |
Technical Indicators
Market Signals| Indicator | TRBG | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 23.09 |
| Support Level | $3.50 | N/A |
| Resistance Level | $3.96 | $2.40 |
| Average True Range (ATR) | 0.35 | 0.21 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 53.76 | 4.07 |
Price Performance
Historical ComparisonAbout TRBG TurboGen Ltd. Ordinary Shares
Turbogen Ltd is engaged in developing multifuel CHP systems with a vision of providing on-site energy for buildings. Its CHP systems outperform current electric efficiency solutions, enabling fast ROI, lower building emissions, and peak saving for utilities. The company's multi-fuel technology enables hybrid Operations: Solar-Gas, Hydrogen-Gas, SOFC-Gas.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.